VivoSim Labs, Inc. (VIVS): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$10.83M

Year ended 2026-03-31

-$10.10M

Trailing 12 months to 2026-06-30

2011-12-31 Operating Cash Flow (USD) 2026-03-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2026-03-31	-$10.83M	n/m	2026-07-14, From 2025-04-01
2025-03-31	-$9.46M	n/m	2026-07-14, From 2024-04-01
2024-03-31	-$14.65M	n/m	2025-06-05, From 2023-04-01
2023-03-31	-$12.41M	n/m	2024-05-31, From 2022-04-01
2022-03-31	-$8.45M	n/m	2023-07-14, From 2021-04-01
2021-03-31	-$13.32M	n/m	2022-06-10, From 2020-04-01
2020-03-31	-$14.88M	n/m	2021-06-15, From 2019-04-01
2019-03-31	-$20.38M	n/m	2020-05-28, From 2018-04-01
2018-03-31	-$28.86M	n/m	2019-06-03, From 2017-04-01
2017-03-31	-$29.18M	n/m	2018-05-31, From 2016-04-01
2016-03-31	-$29.37M	n/m	2018-05-31, From 2015-04-01
2015-03-31	-$19.60M	n/m	2017-06-07, From 2014-04-01
2014-03-31	-$15.56M	n/a	2014-06-10, From 2013-04-01
No annual figure between 2012-12-31 and 2014-03-31.
2012-12-31	-$9.69M	n/m	2013-03-15, From 2012-01-01
2011-12-31	-$1.91M	n/a	2013-03-15, From 2011-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
VivoSim Labs, Inc. (VIVS)	2026-03-31	-$10.83M	n/m
Zivo Bioscience, Inc. (ZIVO)	2024-12-31	-$4.31M	n/m
aTYR PHARMA INC (ATYR)	2025-12-31	-$61.99M	n/m
AIM ImmunoTech Inc. (AIM)	2025-12-31	-$10.96M	n/m
Inmune Bio, Inc. (INMB)	2025-12-31	-$22.58M	n/m
Entera Bio Ltd. (ENTX)	2025-12-31	-$7.37M	n/m
Cardiff Oncology, Inc. (CRDF)	2025-12-31	-$37.92M	n/m
Senti Biosciences Holdings, Inc. (SNTI)	2025-12-31	-$43.44M	n/m
ImageneBio, Inc. (IMA)	2025-12-31	-$47.84M	n/m

Compare VIVS, ZIVO, ATYR, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗